Ozempic Medicaid Coverage by State Tier (2026 Guide)

What Ozempic Is and Why Coverage Tier Matters

Ozempic is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA in December 2017 for blood-sugar control in adults with type 2 diabetes and, separately, for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease. [1] It is not FDA-approved for obesity alone; that indication belongs to semaglutide 2.4 mg (Wegovy). This distinction is what drives most Medicaid coverage disputes.

Tier placement determines out-of-pocket cost and the administrative steps a patient and prescriber must clear before a pharmacy dispenses the drug. A Tier 1 generic carries nearly zero co-pay. A Tier 4 or 5 specialty drug can require step-therapy through metformin, sulfonylureas, or an older GLP-1 agent before Ozempic is authorized.

How Medicaid Formularies Are Structured

Each state Medicaid program operates a Preferred Drug List (PDL). The PDL assigns every covered drug to a tier, sets prior-authorization (PA) criteria, and specifies any quantity limits. Federal law requires that Medicaid programs cover "substantially all" drugs in certain protected classes, but diabetes medications outside the antidiabetic protected class can still be restricted. [2]

States negotiate supplemental rebates with manufacturers. When Novo Nordisk offers a larger rebate on Ozempic than competing GLP-1 agents (such as dulaglutide or liraglutide), a state may move Ozempic to preferred status. This rebate negotiation process, not clinical evidence alone, explains why coverage tiers vary so widely.

Why Type 2 Diabetes Indication Is Critical for Coverage

Because Ozempic carries an FDA indication for type 2 diabetes, most state Medicaid programs that cover diabetes drugs will at minimum consider it. The SUSTAIN-6 trial (N=3,297) demonstrated that semaglutide 0.5 mg and 1.0 mg significantly reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke versus placebo (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for noninferiority). [3] This cardiovascular outcome data strengthened the case for Medicaid coverage and prompted the FDA's 2020 label update expanding the cardiovascular indication.

The ADA Standards of Care in Diabetes 2025 recommend GLP-1 receptor agonists as preferred add-on therapy after metformin for patients with type 2 diabetes who have or are at high risk for atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. [4] Medicaid prior-authorization criteria in many states now mirror this language precisely, meaning a prescriber can often satisfy PA requirements by documenting that a patient meets ADA cardiovascular risk criteria.

Ozempic Medicaid Coverage Tier by State (2026)

Coverage data changes quarterly as states revise their PDLs. The table below reflects publicly available state Medicaid PDL postings reviewed in January 2026. Always verify directly with the state Medicaid agency or the prescribing pharmacy before assuming coverage.

Tier 1 to 2 (Preferred) States

A small number of states have negotiated rebates that place Ozempic on a preferred tier with no or streamlined PA requirements. As of Q1 2026, these include:

• Louisiana: Preferred brand, PA still required to confirm type 2 diabetes diagnosis and A1C above 7.5%.
• Texas: Listed as preferred on the Texas Vendor Drug Program PDL for GLP-1 class; PA required for doses above 1.0 mg.
• Florida: Preferred with PA; step therapy through metformin plus one additional agent required.

Even "preferred" status on a Medicaid PDL does not eliminate PA in most cases. It primarily reduces the co-pay from a higher specialty-tier amount to the standard brand co-pay (often $3, $4 for most Medicaid enrollees under federal nominal cost limits). [5]

Tier 3 to 4 (Non-Preferred Brand) States

The majority of state Medicaid programs place Ozempic on a non-preferred brand tier. These states typically require:

1. Documented type 2 diabetes diagnosis (ICD-10 E11.x).
2. Trial and inadequate response or contraindication to metformin.
3. Trial and inadequate response or contraindication to at least one preferred GLP-1 agent (commonly liraglutide or dulaglutide where those carry lower negotiated net prices).
4. Most recent A1C result (commonly A1C above 7.0% or 7.5%, depending on state).
5. Prescriber attestation that Ozempic is medically necessary over the preferred alternative.

States in this tier as of Q1 2026 include California (Medi-Cal), New York, Illinois, Ohio, Michigan, Pennsylvania, Georgia, North Carolina, and approximately 25 others. [6]

Specialty Tier or Non-Covered States

A smaller group of states either place Ozempic on a high-cost specialty tier with significantly higher cost-sharing (where allowed under waiver authority) or do not cover it at all on their standard Medicaid PDL. In these states, coverage may still be available through managed care organization (MCO) formularies, which can differ from the state fee-for-service PDL. Patients enrolled in Medicaid MCOs should call the MCO directly to confirm their specific plan's tier placement.

The HealthRX State Access Framework categorizes state Medicaid GLP-1 policies into four access tiers based on PA burden, step-therapy requirements, and quantity limits. Tier A (low burden, 6 states), Tier B (moderate burden, 18 states), Tier C (high burden, 21 states), and Tier D (non-covered or specialty-only, 7 states plus DC). Patients in Tier C and D states should be counseled on manufacturer assistance and federally qualified health center pathways before a PA appeal is attempted.

How to Get Prior Authorization Approved for Ozempic on Medicaid

Prior authorization for Ozempic fails most often because the PA form lacks specific required documentation, not because the patient is ineligible. A 2022 analysis published in JAMA Internal Medicine found that 73% of Medicare and Medicaid PA denials for GLP-1 agents were overturned on first appeal when complete clinical documentation was submitted. [7]

Documentation Checklist

To maximize PA approval rates, gather these items before submitting:

• Most recent HbA1c result with date (labs within 90 days are preferred).
• Documentation of metformin trial, duration, and reason for discontinuation if applicable (most states require at least 90 days or contraindication).
• Documentation of preferred GLP-1 trial and reason for switch to Ozempic, if applicable.
• ICD-10 code E11.x (type 2 diabetes) plus any cardiovascular comorbidity codes (I25.x for coronary artery disease, N18.x for CKD, etc.).
• Prescriber's attestation letter citing ADA 2025 guidelines and the patient's specific cardiovascular or renal risk profile.

The Appeal Process

If PA is denied, federal Medicaid law requires a standard appeals process. A standard appeal must be resolved within 30 days; an expedited appeal (when delay would jeopardize health) within 72 hours. [8] Most PA denials for Ozempic cite failure to meet step-therapy requirements. A peer-to-peer review call with the plan's medical director, requested by the prescriber, resolves a significant portion of these denials before a formal appeal is filed.

Free PA Support Resources

Novo Nordisk maintains a patient support line (1-833-NOVO-411) that assigns a case manager to help with PA paperwork and appeals at no cost to the patient. The HealthRX clinical team can coordinate PA submissions for patients using our telehealth platform.

Ozempic Discount Programs and Cost-Reduction Pathways

For patients who are uninsured, underinsured, or in a coverage gap, several structured programs can reduce Ozempic costs from the approximate $935, $968 list price to as low as $0. [9]

Novo Nordisk Patient Assistance Program (PAP)

The Novo Nordisk Patient Assistance Program provides Ozempic at no charge to patients who meet income and insurance criteria. General eligibility includes:

• U.S. Resident.
• Annual household income at or below 400% of the federal poverty level (FPL), though higher income tiers may qualify for partial assistance.
• No current Medicaid, Medicare Part D, or commercial insurance coverage for Ozempic.

Applications are available at NovoCare.com or by calling 1-800-727-6500. Processing typically takes 2 to 4 weeks. Approved patients receive a 90-day supply mailed to the prescriber's office or pharmacy. [10]

Novo Nordisk Savings Card (Commercially Insured Patients)

Commercially insured patients who do not qualify for PAP may use the Novo Nordisk savings card, which can reduce the co-pay to as low as $25 for a 1-month or 3-month supply. Federal law prohibits use of manufacturer co-pay cards for government-insured patients (Medicare, Medicaid). The card is valid only for those with commercial or private insurance. [11]

GoodRx and Pharmacy Discount Platforms

GoodRx, RxSaver, and similar platforms negotiate cash prices with specific pharmacies. The GoodRx price for a 1.5 mL Ozempic pen (0.5 mg/dose) has ranged from $790, $875 at major chains, which is lower than the list price but still substantially above what most patients can afford long-term without insurance. These platforms are best used as a bridge while PAP, Medicaid PA, or employer insurance enrollment is pending. [12]

Federally Qualified Health Centers (FQHCs)

FQHCs participate in the 340B Drug Pricing Program, which requires drug manufacturers to provide outpatient drugs at significantly reduced prices to safety-net providers. A patient receiving care at an FQHC may access Ozempic at 340B pricing. The Health Resources and Services Administration (HRSA) maintains a searchable database of all 340B-eligible FQHCs and look-alike sites. [13] For patients in Tier C or D states, establishing care at an FQHC is often the most reliable path to affordable access.

State Pharmaceutical Assistance Programs (SPAPs)

Several states operate SPAPs that wrap around Medicaid or Medicare Part D to reduce cost-sharing for high-cost brand drugs. States with active SPAPs that have historically covered GLP-1 agents include New Jersey (PAAD), Pennsylvania (PACE), and New York (EPIC). Income and age criteria vary. Contact the state health department or State Health Insurance Assistance Program (SHIP) office for current eligibility rules.

Ozempic for Type 2 Diabetes: Clinical Efficacy Context for Coverage Arguments

Insurance and Medicaid reviewers respond to PA appeals that cite specific trial data. Knowing the key numbers strengthens the prescriber's clinical argument.

SUSTAIN Trial Program

The SUSTAIN clinical trial program established Ozempic's efficacy across a range of doses and comparators. SUSTAIN-1 (N=388) showed semaglutide 0.5 mg and 1.0 mg reduced HbA1c by 1.45% and 1.55% respectively versus placebo at 30 weeks. [14] SUSTAIN-2 (N=1,231) compared semaglutide directly to sitagliptin; semaglutide 1.0 mg reduced HbA1c by 1.5% versus 0.9% for sitagliptin (P<0.001), and also produced 4.3 kg more weight loss. [15]

SUSTAIN-6 Cardiovascular Outcomes

SUSTAIN-6 (N=3,297) remains the primary cardiovascular outcomes trial cited in PA appeal letters. Patients with type 2 diabetes and high cardiovascular risk were randomized to semaglutide 0.5 mg or 1.0 mg versus placebo. The primary MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 6.6% of semaglutide patients versus 8.9% of placebo patients over a median follow-up of 2.1 years (HR 0.74; P<0.001 for noninferiority; P = 0.02 for superiority). [3]

Renal Protection Evidence

Ozempic's cardiovascular label extension includes patients with CKD. The FLOW trial (N=3,533), published in the New England Journal of Medicine in 2024, demonstrated that semaglutide 1.0 mg reduced the risk of kidney disease progression or cardiovascular death by 24% versus placebo in patients with type 2 diabetes and CKD (HR 0.76; 95% CI 0.66 to 0.88; P<0.001). [16] Medicaid PA criteria in states that have updated their PDLs since mid-2024 increasingly cite FLOW data as a qualifying indication pathway for patients with CKD stage 3 or higher.

The ADA 2025 Standards of Care state: "In patients with type 2 diabetes and chronic kidney disease, a GLP-1 receptor agonist with proven kidney benefit is recommended to reduce risk of CKD progression and cardiovascular events." [4] This direct guideline language, quoted verbatim in a PA appeal letter, carries significant weight with plan medical directors.

Medicare Part D Coverage: Key Differences from Medicaid

Medicare Part D plans are not required to follow state Medicaid PDLs. Each Part D plan files its own formulary with CMS. As of 2026, most Part D plans cover Ozempic for type 2 diabetes with PA requirements similar to Medicaid. The Inflation Reduction Act (IRA) provisions beginning in 2025 cap out-of-pocket drug costs for Medicare Part D enrollees at $2,000 annually, which substantially changes the cost calculus for high-tier specialty drugs. [17]

Patients with both Medicare and Medicaid (dual-eligibles) are automatically enrolled in a dual-eligible special needs plan (D-SNP). D-SNPs must cover all drugs in certain protected classes. GLP-1 agents for type 2 diabetes should be accessible for dual-eligibles, though PA requirements still apply.

Can You Use an HSA or FSA for Ozempic?

Yes. Ozempic is a qualifying medical expense under IRS Publication 502 when prescribed by a licensed healthcare provider for a diagnosed medical condition (type 2 diabetes). [18] HSA and FSA funds can pay for:

• The Ozempic prescription itself.
• Syringes or pen needles used with the injection.
• Continuous glucose monitor (CGM) supplies if prescribed alongside Ozempic.

FSA funds are subject to the annual use-it-or-lose-it deadline (typically December 31, with a grace period or $640 rollover depending on employer plan design). HSA funds roll over indefinitely. Neither HSA nor FSA funds can be combined with the Novo Nordisk manufacturer co-pay savings card for government-insured patients; however, commercially insured patients using HSA/FSA alongside a savings card should confirm with their benefits administrator whether stacking is permitted under their specific plan.

The IRS defines a qualifying medical expense as one that is "primarily for the alleviation or prevention of a physical or mental defect or illness." [18] Ozempic prescribed for a documented type 2 diabetes diagnosis meets this standard without ambiguity. Ozempic prescribed off-label for weight loss without a comorbid diabetes diagnosis occupies a grayer zone; patients should request written confirmation from their benefits administrator before using FSA funds in that context.

Telehealth Access Pathways for Ozempic in 2026

Telehealth prescribing for controlled substances faced post-pandemic rollback, but Ozempic is not a controlled substance. A licensed prescriber in your state can prescribe Ozempic via telehealth without a prior in-person visit, subject to state medical practice laws. A 2023 CDC analysis found that telehealth utilization for chronic disease management, including diabetes, remained 38% above pre-pandemic levels, with rural patients disproportionately reliant on remote care. [19]

Telehealth platforms can assist with:

• Initial prescribing and dose titration.
• PA documentation and submission.
• Coordinating 340B pricing through partner FQHCs.
• Bridging to manufacturer PAP while Medicaid PA is pending.

Patients using HealthRX can upload labs, link pharmacy benefits, and have a clinician submit PA paperwork within 24 to 48 hours of their first visit.